CliMB-325 

CliMB-325 is an HSP90 inhibitor that can induce MHC-I (EC₅₀ = 498 nM) expression on the surface of CT26 murine colorectal cancer cells. CliMB-325 enhances T cell activation and exhibits lower toxicity. CliMB-325 can be used for the study of colorectal cancer^[1].

CliMB-325 induces MHC-I (EC₅₀ = 498 nM) expression on the surface of CT26 murine colorectal cancer cells^[1].
CliMB-325 exhibits low cytotoxicity against CT26 murine colorectal cancer cells with a CC₅₀ of 1.3 μM^[1].
CliMB-325 (1 μM, 48 h) increases T cell activation (measured by β-galactosidase activity) by 1.6-fold when MC38-OVA cells, after a 48-hour incubation, are co-cultured with B3Z T cells^[1].
CliMB-325 adds 290 unique MHC-I peptides, five times more than the untreated group, and 81.3% of the peptides are unique to the CliMB-325 group^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

386.20

C₁₅H₉Cl₂N₉

ClC1=C2N=CN(C2=NC(N)=N1)CC3=CN(N=N3)C4=CC=C(C=C4C#N)Cl

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Newkirk SE, et al. Small Molecule Modulation of MHC-I Surface Expression: A Click Chemistry-Based Discovery Approach. J Med Chem. 2025 Nov 13;68(21):22301-22311.